Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer

The goal of this Phase I/II trial is to assess the safety and efficacy of administering durvalumab concurrent with weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide (ddAC) neoadjuvant therapy for stages I–III triple-negative breast cancer. The primary endpoint is pathologic complete...

Descripción completa

Detalles Bibliográficos
Autores principales: Foldi, Julia, Silber, Andrea, Reisenbichler, Emily, Singh, Kamaljeet, Fischbach, Neal, Persico, Justin, Adelson, Kerin, Katoch, Anamika, Horowitz, Nina, Lannin, Donald, Chagpar, Anees, Park, Tristen, Marczyk, Michal, Frederick, Courtney, Burrello, Trisha, Ibrahim, Eiman, Qing, Tao, Bai, Yalai, Blenman, Kim, Rimm, David L., Pusztai, Lajos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7870853/
https://www.ncbi.nlm.nih.gov/pubmed/33558513
http://dx.doi.org/10.1038/s41523-021-00219-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7870853/
https://www.ncbi.nlm.nih.gov/pubmed/33558513
http://dx.doi.org/10.1038/s41523-021-00219-7

Ejemplares similares